Confluent and reticulated papillomatosis (CRP) is a relatively rare disease manifested by grayish-brown verrucous papules localized to the intermammary and interscapular regions [lj. The papules coalesce into plaques and those at the periphery spread out and form a pigmented reticulated pattern. The cause of the disease has not been clarified, however, 'a genetically determined defect of keratini -zation' could be an explanation [2]. Calcipotriol has been found effective in diseases of keratinization [3]. This prompted us to employ calcipotriol in a patient with CRP. A 25-year-old white female patient was referred for a 1-year history of slightly itchy skin lesions on the trunk. Family history was negative for similar lesions. Dermatologic examination disclosed 3-to 4-mm-sized flat-topped, red-brown keratotic papules that formed plaques in a reticulated manner in the intermammary region, abdomen and interscapular area. The mucous membranes and other skin areas were free of lesions. Histo-pathologic examination of a 5-mm punch biopsy specimen disclosed epidermal hyper-keratosis, a decrease in granular layer and thinning of the rete ridges which were consistent with a diagnosis of CRP. Laboratory investigations revealed normal findings. A potassium hydroxide preparation was negative for Pityrosporum orbiculare. The patient was started on calcipotriol ointment (50 µg/g) with twice-daily application and at doses of 100 g/week. Baseline serum adjusted calcium was 2.28 mmol/l (normal range 2.25-2.55 mmol/l). Regular calcium measurements were repeated on days 15 and 30 of the treatment and were found 2.40 and 2.54 mmol/l, respectively. The lesions subsided and showed considerable improvement within 4 weeks. The patient did not show any flare-ups, and was lesion free 1 month after the treatment. Serum-adjusted calcium level assessed 2 weeks after discontinuation of calcipotriol ointment was 2.50 mmol/l. CRP was first described by Gougerot and Carteaud [1] 
The vitamin D3 analogue calcipotriol has been shown to be a potent regulator of cell differentiation and an inhibitor of cell proliferation in human keratinocytes [4] [5] [6] [7] [8] . Calcipotriol has also been found effective in reducing markers of abnormal keratinization (expression of keratin 16) [6, 7] . At present, calcipotriol ointment is only licensed for use in chronic plaque psoriasis. However, it could be of benefit in certain conditions like pityriasis rubrapilaris [9] . Our observation supports the view that CRP could be regarded as a disease of keratinization and that calcipotriol ointment could be of use in the management of the disease. The major concern about calcipotriol is its effect on calcium metabolism. At doses of 100 g/week, calcipotriol is generally considered to be safe with respect to any changes in calcium levels [5, 8] . However, hypercalce-mia was reported in a case of extensive psoriasis treated with less than 100 g calcipotriol/ week [10] . In our case, serum-adjusted calcium level was slightly increased, but remained in the normal range.
